This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Thompson, S. G Articles by Warn, D. E Search for Related Content PubMed PubMed Citation Articles by Thompson, S. G Articles by Warn, D. E Social Bookmarking                         What's this?

Multilevel models for meta-analysis, and their application to absolute risk differences

MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK

Rebecca M Turner

MRC Clinical Trials Unit, London, UK

David E Warn

MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK

Meta-analysis can be considered a multilevel statistical problem, since information within studies is combined in the presence of potential heterogeneity between studies. Here a general multilevel model framework is developed for meta-analysis to combine either summary data or individual patient outcome data from each study, and to include either study or individual level covariates that might explain heterogeneity. Classical and Bayesian approaches to estimation are contrasted. These methods are applied to a meta-analysis of trials of thrombolytic therapy after myocardial infarction. Subgroups within the trials were available, categorized by the time delay until treatment, so that a three-level random effects model that includes time delay as a covariate is proposed. In addition it was desired to represent the treatment effect as an absolute risk reduction, rather than the conventional odds ratio. We show how this can be achieved within a Bayesian analysis, while still recognizing the binary nature of the original outcome data.

Statistical Methods in Medical Research, Vol. 10, No. 6, 375-392 (2001)
DOI: 10.1177/096228020101000602


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Liberati, D. G Altman, J. Tetzlaff, C. Mulrow, P. C Gotzsche, J. P A Ioannidis, M. Clarke, P J Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ, December 4, 2009; 339(jul21_1): b2700 - b2700. [Abstract] [Full Text] [PDF]

				A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche, J. P.A. Ioannidis, M. Clarke, P. J. Devereaux, J. Kleijnen, and D. Moher The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration Ann Intern Med, August 18, 2009; 151(4): W-65 - W-94. [Abstract] [Full Text] [PDF]

				D. A Bennett Review of analytical methods for prospective cohort studies using time to event data: single studies and implications for meta-analysis Statistical Methods in Medical Research, August 1, 2003; 12(4): 297 - 319. [Abstract] [PDF]